RxDoctor Payments Data

Manuel Katz, MD

Internal Medicine · Englewood, NJNPI 1376541359

Payments from drug & device makers

$2,212in general payments, 2019–2025

Across 56 payments — averaging $39.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$993
  • AbbVie$555
  • Merck$98
  • Lilly USA, LLC$93
  • Novo Nordisk$84
  • Exact Sciences$67
  • plus $323 from 13 others

What the payments were for

  • Consulting fees$97544%
  • Food & beverage$1,23756%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,212 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$244,555
Medicare patients
650
Services billed
3,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide81$104,342
JanuviaSitagliptin Phosphate68$81,181
EliquisApixaban48$66,648
JardianceEmpagliflozin63$66,037
OzempicSemaglutide39$56,919
TrulicityDulaglutide25$23,214
RestasisCyclosporine13$7,423
Enoxaparin Sodium11$7,194
Atorvastatin Calcium603$6,305
Arnuity ElliptaFluticasone Furoate17$5,358
Rosuvastatin Calcium272$5,262
SynthroidLevothyroxine Sodium51$3,446
Levothyroxine Sodium269$2,707
Duloxetine Hcl30$2,586
Losartan Potassium200$2,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$93$127,556106 claims
MerckJanuvia$98$81,18168 claims
Novo NordiskOzempic$84$56,91939 claims
AbbVieRestasis, Synthroid$555$10,86964 claims
GSKArnuity Ellipta$17$5,35817 claims
Scilex Pharmaceuticals Inc.Colchicine$11$82320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →